Coffee, a widely consumed beverage, contains various compounds like polyphenols and caffeine that interact with the human body in complex ways. A recent comprehensive review published in the journal Metabolites meticulously examined the gastrointestinal processing, systemic absorption, and microbial transformation of these coffee constituents. The findings underscore how different preparation methods, from roasting to brewing, can significantly alter the chemical profile of coffee, thereby modulating its effects on gut health and overall metabolism.
Observational studies have frequently associated regular coffee consumption with beneficial health outcomes, such as a reduced risk of type 2 diabetes and improved liver function. However, these studies often fall short of establishing a definitive causal link and fully elucidating the role of gut microorganisms in these associations. Caffeine, a well-known stimulant in coffee, is rapidly absorbed in the upper gastrointestinal tract and metabolized by the liver. Its direct impact on gut microbiota is believed to be indirect, as it is not typically fermented by colonic bacteria. Despite this, high caffeine intake has been correlated with changes in the diversity and composition of gut bacterial communities.
Chlorogenic acids (CGAs), another significant class of polyphenols in coffee, largely escape absorption in the upper GI tract. They then undergo transformation by microbes in the colon. This process involves esterase-producing bacteria like Eubacterium ramulus and Bifidobacterium, which initiate the hydrolysis of CGAs. The resulting caffeic acid is further broken down into various low-molecular-weight phenolic acids, some of which are absorbed and conjugated in the gut and liver before entering systemic circulation. Laboratory studies have indicated that purified CGAs and coffee extracts can selectively influence the growth of certain bacterial species and promote the synthesis of different phenolic acids.
The roasting process of coffee beans leads to the formation of high-molecular-weight melanoidins and structural changes in coffee polysaccharides. Components of these carbohydrate-melanoidin complexes, as well as soluble polysaccharides and bound phenolics, resist digestion in the upper GI tract and reach the colon. In the colon, galactomannans and arabinogalactans, key cell-wall polysaccharides in coffee beans, can be microbially degraded to produce short-chain fatty acids (SCFAs). The fermentation of arabinogalactan-rich coffee fractions also generates dihydroferulic and dihydrocaffeic acid. While melanoidin-rich fractions may influence colonic fermentation, their impact on microbial bile acid transformation remains unclear.
The method of brewing profoundly influences the chemical composition of the final coffee beverage. Factors such as water temperature, contact duration, pressure, grind size, and filtration all affect the extraction of compounds. Consequently, different brewing styles like espresso, drip-filtered, French press, boiled, cold-brew, and instant coffee yield varying proportions of compounds that eventually reach the colon. These variations can alter the substrates available to gut microbes. However, no single brewing method has been definitively shown to offer a consistent microbiome or metabolic advantage in humans. Filtration, particularly with paper filters, has a notable health implication: it reduces levels of cafestol and kahweol, compounds linked to elevated LDL cholesterol when unfiltered coffee is consumed regularly.
Short-chain fatty acids (SCFAs), produced by the fermentation of nondigestible coffee fractions by intestinal microbiota, are considered potential mediators of coffee's metabolic effects. These include butyrate, acetate, and propionate, which have been observed in in vitro studies. Free and bound polyphenols may also impact SCFA profiles by altering the composition of microbial communities and their substrate preferences. CGAs, caffeic acid, and other phenolic compounds have been implicated in various inflammatory, metabolic, and redox signaling pathways in animal and cell culture models. Microbial bile acid transformation represents another possible mechanism linking coffee to the regulation of the liver-gut axis. Preclinical studies involving CGAs or caffeine have demonstrated changes in the serum metabolome, including aspects of bile acid metabolism. Microbes modify the bile acid pool through deconjugation, oxidation, dehydroxylation, and epimerization, converting primary bile acids into secondary bile acids.
These bile acids and their microbial derivatives serve as ligands for G protein-coupled bile acid receptor 1 (TGR5) and farnesoid X receptor (FXR), which play crucial roles in regulating metabolic and immune responses. In mouse models, intestinal FXR activation has been shown to enhance fibroblast growth factor 15 (FGF15) secretion, contributing to the feedback regulation of bile acid synthesis. Humans possess a similar fibroblast growth factor 19 (FGF19) pathway. Furthermore, TGR5 activation can modulate glucagon-like peptide 1 (GLP-1) release and immune cell function. Despite these promising findings, clinical studies directly demonstrating coffee's effects on metabolic outcomes through bile acid receptor pathways are still limited.
Despite the growing body of research, several limitations hinder drawing firm clinical or mechanistic conclusions. Many studies utilize purified caffeine, extracts, or CGAs, or employ experimental doses that do not accurately reflect the exposure and composition of coffee typically consumed. Furthermore, evidence regarding microbial responses often relies solely on taxonomic abundance, lacking parallel measurements of microbial pathways or metabolite production. The observed associations between coffee consumption, cardiometabolic outcomes, and microbial features do not necessarily imply that these effects are mediated by the gut microbiota. Future research should prioritize developing standardized coffee exposure platforms. These platforms should compare decaffeinated and caffeinated coffee against non-coffee controls, while carefully regulating brewing methods, filtration, roasting levels, dosages, and additives. Translating existing evidence into precise coffee nutrition strategies necessitates studies that use realistic doses and focus on clinically meaningful outcomes. This will depend on whether experimental doses replicate achievable human exposures, biomarkers effectively capture the heterogeneity in exposure and response, and potential benefits remain favorable after accounting for safety, individual susceptibility, and beverage preparation methods.